Meeting Coverage:

American Academy of Ophthalmology

AAO: 2018

Phase 3 CEDAR and SEQUOIA Clinical Trial Results

Show Description +

Rahul N. Khurana, MD, discusses the phase 3 results of the CEDAR and SEQUOIA double masked, randomized controlled clinical trials that evaluated over 1800 patients comparing abicipar pegol (Allergan) with ranibizumab (Lucentis, Genentech) for the treatment of neovascular age-related macular degeneration.

Posted: 10/29/2018

Up Next


New IOL Technologies

Amr M. Kouchouk, MD, Kendall E. Donaldson, MD, MS, Vance M. Thompson, MD, FACS

Topical Retina Treatments

Carl D. Regillo, MD, FACS, Caroline R. Baumal, MD, Michael A. Singer, MD

Refractive Residencies

George O. Waring IV, MD, FACS , Osama Ibrahim, MD, Renato Ambrosio Jr, MD, PhD

Take-Home Points for APL-2

David S. Boyer, MD

Customizing the IOL

George O. Waring IV, MD, FACS

Anatomy in HAWK and HARRIER

Pravin U. Dugel, MD

Phase 3 CEDAR and SEQUOIA Clinical Trial Results

Rahul N. Khurana, MD, discusses the phase 3 results of the CEDAR and SEQUOIA double masked, randomized controlled clinical trials that evaluated over 1800 patients comparing abicipar pegol (Allergan) with ranibizumab (Lucentis, Genentech) for the treatment of neovascular age-related macular degeneration.

Posted: 10/29/2018


Please log in to leave a comment.

More From AAO: 2018 Coverage

Anatomy in HAWK and HARRIER

Pravin U. Dugel, MD

New IOL Technologies

Amr M. Kouchouk, MD, Kendall E. Donaldson, MD, MS, Vance M. Thompson, MD, FACS